Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~1. Approved for cardiac transplantation~2. Listed with UNOS on the Status 1 list~3. Patient for whom LVAS implantation is planned as a clinically indicated bridge to cardiac transplantation~Exclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~1. Contraindication to the administration of warfarin or anti-platelet agents~2. Primary coagulopathy or platelet disorder~3. Acute myocardial infarction within 48 hours prior to enrollment~4. Anticipated need for RVAD support or ECMO at the time of LVAS implantation~5. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty, passive restraint device (i.e., CorCapTM Cardiac Support Device) or surgically implanted left ventricular assist device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Historical Data (Type: OTHER): DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients

Based on this trial design, predict the completion outcome and termination type (if applicable).